Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Targeted Oncology
|
August 20, 2015
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study
Christelle de la Fouchardiere, Nadia Oussaid, Olfa Derbel, et al.
Plos One
|
February 4, 2017
Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)
Olfa Derbel, Pierre Etienne Heudel, Claire Cropet, et al.
BMC Cancer
|
February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
Jean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
Breast Cancer (Dove Medical Press)
|
May 4, 2023
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
Benoîte Mery, Christine Ménétrier-Caux, Laure Montané, et al.
Breast (Edinburgh, Scotland)
|
December 3, 2019
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14)
Frédérique Penault-Llorca, Fabrice Kwiatkowski, Antoine Arnaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Séverine Guiu, Judith Balmaña, Pablo Lemercier, et al.
Breast (Edinburgh, Scotland)
|
November 28, 2025
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03
Olivier Trédan, Delphine Loirat, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2017
Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer
S Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, et al.
Nature Communications
|
July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme
Romain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Targeted Oncology
|
August 20, 2015
Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study
Christelle de la Fouchardiere, Nadia Oussaid, Olfa Derbel, et al.
Plos One
|
February 4, 2017
Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort)
Olfa Derbel, Pierre Etienne Heudel, Claire Cropet, et al.
BMC Cancer
|
February 8, 2013
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
Jean-Yves Blay, Antoine Italiano, Isabelle Ray-Coquard, et al.
Breast Cancer (Dove Medical Press)
|
May 4, 2023
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
Benoîte Mery, Christine Ménétrier-Caux, Laure Montané, et al.
Breast (Edinburgh, Scotland)
|
December 3, 2019
Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14)
Frédérique Penault-Llorca, Fabrice Kwiatkowski, Antoine Arnaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Séverine Guiu, Judith Balmaña, Pablo Lemercier, et al.
Breast (Edinburgh, Scotland)
|
November 28, 2025
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03
Olivier Trédan, Delphine Loirat, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2017
Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian Cancer
S Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, et al.
Nature Communications
|
July 16, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
Isabelle L Ray-Coquard, Aude-Marie Savoye, Camille Schiffler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme
Romain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Page
of 3